Renalytix AI (GB:RENX) has released an update.
Renalytix plc, a leader in AI-enabled in-vitro diagnostics for kidney health, has announced a switch of its US accounting firm to CohnReznick LLP for the fiscal year ending June 30, 2024, replacing Ernst & Young LLP. CEO James McCullough expresses the company’s focus on improving cost efficiencies and increasing revenue, emphasizing the reallocation of resources towards sales and marketing efforts. The company’s kidneyintelX.dkd test has been recognized as an FDA-authorized prognostic tool for early-stage kidney disease in Type 2 diabetes patients.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
